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Cognitive and Motor Outcomes of Children with Prenatal Opioid Exposure: A
Systematic Review and Meta-analysis
Abstract
Importance Prenatal opioid exposure (POE) is one of the fastest-growing global health problems, but its
association with long-term neurologic and physical development remains unknown.
Objective To assess the association between POE and cognitive and motor development in children from
age 6 months to 18 years.
Data Sources Key search terms included prenatal opioid exposure, neonatal abstinence syndrome, and
neurocognitive development. Studies were searched using PubMed and Embase, with no publication date
restriction, through August 20, 2018.
Study Selection Only published cohort studies comparing the results of age-appropriate standardized
cognitive and/or motor tests between children with any POE (aged 0-18 years) with drug-free controls
were included. Data that were not convertible to means and SDs were excluded.
Data Extraction and Synthesis This study was conducted according to Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA) and Meta-analysis of Observational Studies in
Epidemiology (MOOSE) guidelines. Data were pooled using a random-effects model.
Main Outcomes and Measures Standardized mean difference of cognitive and motor tests between POE
and nonexposed children.
Results Twenty-six peer-reviewed cohort studies were included. Cognitive outcomes were compared for a
total of 1455 children with POE and 2982 nonexposed children across 3 age groups (mean [SE] age at
cognitive testing was 13 [1.58] months for the toddler group; 4.5 [0.38] years for the preschool group; and
13 [2.36] years for the school-aged group). Motor outcomes were compared for 688 children with POE
and 1500 nonexposed children up to age 6 years (mean [SD] age at motor testing, 2 [0.45] years).
Standardized mean difference was lower in cognitive tests for children with POE at 0 to 2 years (d =
−0.52; 95% CI, −0.74 to −0.31; P < .001) and 3 to 6 years (d = −0.38; 95% CI, −0.69 to −0.07; P < .001); the
difference was not significant for those aged 7 to 18 years (d = −0.44; 95% CI, −1.16 to 0.28; P = .23).
Motor scores were lower in children with POE (d = 0.49; 95% CI, 0.23-0.74; P < .001).
Conclusions and Relevance Prenatal opioid exposure appeared to be negatively associated with
neurocognitive and physical development from age 6 months, and this association persisted until
adolescence. The cause and association of this with POE or other factors (eg, withdrawal treatment) are
uncertain but suggest that POE necessitates long-term support and intervention.
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Abstract

Key Points

IMPORTANCE Prenatal opioid exposure (POE) is one of the fastest-growing global health problems,
but its association with long-term neurologic and physical development remains unknown.

Question Is prenatal opioid exposure
associated with differences in childhood
cognitive and motor development?

OBJECTIVE To assess the association between POE and cognitive and motor development in

Findings In this systematic review and

children from age 6 months to 18 years.

meta-analysis of 26 studies including
1455 children exposed to prenatal

DATA SOURCES Key search terms included prenatal opioid exposure, neonatal abstinence

opioids compared with unexposed

syndrome, and neurocognitive development. Studies were searched using PubMed and Embase, with

children, prenatal opioid exposure was

no publication date restriction, through August 20, 2018.

associated with lower cognitive scores.
The largest difference was seen

STUDY SELECTION Only published cohort studies comparing the results of age-appropriate
standardized cognitive and/or motor tests between children with any POE (aged 0-18 years) with
drug-free controls were included. Data that were not convertible to means and SDs were excluded.

between ages 6 months and 6 years.
Meaning The negative consequences
of prenatal opioid exposure on
neurocognitive and physical

DATA EXTRACTION AND SYNTHESIS This study was conducted according to Preferred Reporting
Items for Systematic Reviews and Meta-analyses (PRISMA) and Meta-analysis of Observational
Studies in Epidemiology (MOOSE) guidelines. Data were pooled using a random-effects model.
MAIN OUTCOMES AND MEASURES Standardized mean difference of cognitive and motor tests

development appear to be present from
6 months and persist beyond
school age.

between POE and nonexposed children.

+ Supplemental content

RESULTS Twenty-six peer-reviewed cohort studies were included. Cognitive outcomes were

Author affiliations and article information are
listed at the end of this article.

compared for a total of 1455 children with POE and 2982 nonexposed children across 3 age groups
(mean [SE] age at cognitive testing was 13 [1.58] months for the toddler group; 4.5 [0.38] years for
the preschool group; and 13 [2.36] years for the school-aged group). Motor outcomes were
compared for 688 children with POE and 1500 nonexposed children up to age 6 years (mean [SD]
age at motor testing, 2 [0.45] years). Standardized mean difference was lower in cognitive tests for
children with POE at 0 to 2 years (d = −0.52; 95% CI, −0.74 to −0.31; P < .001) and 3 to 6 years
(d = −0.38; 95% CI, −0.69 to −0.07; P < .001); the difference was not significant for those aged 7 to
18 years (d = −0.44; 95% CI, −1.16 to 0.28; P = .23). Motor scores were lower in children with POE
(d = 0.49; 95% CI, 0.23-0.74; P < .001).
CONCLUSIONS AND RELEVANCE Prenatal opioid exposure appeared to be negatively associated
with neurocognitive and physical development from age 6 months, and this association persisted
(continued)
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Abstract (continued)

until adolescence. The cause and association of this with POE or other factors (eg, withdrawal
treatment) are uncertain but suggest that POE necessitates long-term support and intervention.
JAMA Network Open. 2019;2(7):e197025. doi:10.1001/jamanetworkopen.2019.7025

Introduction
Prenatal opioid exposure (POE) is a fast-growing health problem, with at least 1 in 5 pregnant women
in high-income countries known to have used some form of opioid during pregnancy.1 This incidence
has been reported to be associated with increases in the risk of perinatal problems, including
neonatal abstinence syndrome (NAS), prematurity, and low birth weight.2 Neonatal abstinence
syndrome affects 75% to 90% of all infants with POE1 and is considered a major global public health
issue. The number of babies affected by NAS has increased by more than 400% in the past 2
decades,3 resulting in consumption of health care and social resources. Public expenditure on
hospital care for newborns with NAS in the United States alone exceeds $1 billion US dollars per year.3
The outcomes of infants with POE are therefore relevant, especially in regard to
neurodevelopment. In animal studies, opioids impair neuronal development, differentiation, growth,
and survival,4,5 as well as neurotransmitter homeostasis.6,7 Changes in brain volume and function
are evident even after short-term opioid use in adult humans.8 Prenatal opioid exposure is also
associated with a higher risk of exposure to adverse social, environmental, and familial disadvantages
that may impede optimal neurodevelopment.9 For example, opioid-using mothers often have poorer
educational attainment,10 an increased risk of psychiatric comorbidity,11 and poorer physical health12
that, together with other problems (eg, poverty, inadequate nutrition, and social chaos), may impair
their ability to nurture their children.
There are minimal data on long-term outcomes of children with POE. Most children with POE
are healthy and have no other medical issues, making the expense for long-term follow-up difficult to
justify.13 Families affected by POE may also be mobile. In Australia, more than 50% of children of
mothers in the methadone program are placed in foster care by age 5 and are subjected to various
home placements and name changes,14 making long-term tracking difficult.
Nevertheless, there is increasing evidence that neurodevelopmental surveillance and
intervention for children with POE should be as important as follow-up for children with other
problems (eg, prematurity). Opioids cross the placental and milk barriers and are easily detectable in
newborn and fetal products.15 The exact association between opioids and neurogenesis and function
is unclear, but opioids have been shown to induce apoptosis of human brain cell cultures in vitro5
and impair synaptosomal uptake of neurotransmitters, such as dopamine and norepinephrine, in
mice.7 In human studies, children with a history of POE have smaller head circumferences16 and
lower brain volumes, especially of the basal ganglia and cerebellum,17 than other children, and these
changes persist to adolescence.18 The association with function is unclear, but in the general
population, smaller brain volumes are reported as being associated with lower intelligence and
cognitive skills.19
Individual neurodevelopmental tests are robust indicators of child functioning. They serve to
inform on the developmental needs of the child so that intervention therapies can be provided to
decrease the risk of future functional problems. However, these tests are time consuming and
difficult to conduct, especially with a mobile and chaotic population. Currently available
neurodevelopmental data for children with POE arise from small, heterogeneous studies that,
individually, are inadequately powered to inform on the needs of this group of children.
We therefore conducted a systematic review and meta-analysis of cohort studies to determine
whether association exists between POE and neurodevelopmental outcomes in children aged 0 to
18 years. We hypothesized that POE will be negatively associated with long-term cognitive and motor
outcomes and that this association will be apparent before the child enters school.
JAMA Network Open. 2019;2(7):e197025. doi:10.1001/jamanetworkopen.2019.7025 (Reprinted)
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Methods
This systematic review and meta-analysis was conducted and reported using the guidelines for Metaanalysis of Observational Studies in Epidemiology (MOOSE)20 and the Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA) reporting guideline.21

Eligibility Criteria
Only published cohort studies that compared outcomes of children with POE (aged 0-18 years) with
drug-free controls were included. Included studies measured cognitive and/or motor development
using age-appropriate, standardized tests and reported results as a mean and SD. Studies without
enough data necessary to derive the mean and SD were excluded. All types of opioids were included,
such as heroin, methadone, and buprenorphine, as well as known polysubstances (ie, >1 class of
drug). Studies were excluded if they did not include human participants, were literature reviews, and
did not have drug-free controls as comparators (Figure 1). To our knowledge, there have been no
randomized clinical trials of POE vs no exposure.

Electronic Search Method and Study Selection
Electronic databases (PubMed and Embase) were searched comprehensively by 2 of us
independently (S.L.Y., J.L.O.). Hand searching was also conducted for references of included studies
and those of relevant reviews. Backward searching looking for other articles by the same authors
was also used, especially for longitudinal cohort studies. A strategy using the search terms prenatal
exposure, opioid, methadone, heroin, neonatal abstinence syndrome, cognition, school, academic
achievement, intelligence, and neurodevelopment was conducted with no publication date
restriction. Articles had to be published in English and as the complete study. The initial search began
on June 12, 2018, and continued concurrently with data extraction until August 10, 2018. Three of us
(S.L.Y, R.M., and J.L.O.) assessed eligibility by title and abstract screening, and any discrepancies were
discussed among all authors with a full-text article review. Study authors were not contacted for
further information owing to the protracted amount of time from when some of the studies were
conducted (>20 years).

Figure 1. PRISMA Flow Diagram of Search
1092 Records identified through
database searching

11 Additional records identified
through other sources

1095 Records after duplicates removed
906 Records excluded (eg, animal
studies, literature reviews)
189 Records screened
52 Full-text articles assessed for eligibility
26 Full-text articles excluded
4 No drug-free controls
8 Standardized tests or scores not used
5 Scores not given as mean (SD)
5 Overlapping study sample
3 Data only on cocaine use
1 Age at testing not specified
26 Studies included in meta-analysis
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Data Extraction
Data extracted from each eligible study included type of exposure to opioids and other drugs, place
of birth, rate of NAS, rate of out-of-home placement, age, and types of neurodevelopmental tests
used and their outcomes. For longitudinal studies that assessed children several times over years and
if results were published in 1 or multiple articles, only 1 result was selected for each age subgroup. For
cognitive outcomes, selection was based first on the largest sample size followed by the age closest
to the mean age for that subgroup. For motor outcomes, selection was based on the largest sample
size followed by the most recent test.22 The subgroups were infancy (ⱕ24 months), preschool age
(3-6 years), and school age (7-18 years).

Statistical Analysis
The main outcome measures were standardized mean differences (SMDs) and 95% CIs, calculated
from the means and SDs of neurodevelopmental tests for POE and unexposed children. Standard
meta-analytic procedures were conducted with the Cochrane Collaboration Review Manager
Software (RevMan, version 5.3) and Meta-Analyst.23 Publication bias and funnel plots were assessed
and generated using Meta-Essentials. Because the studies used different assessment tools, a random
effects model24 was used to calculate SMD, which was used as effect size per Cohen d (0.3-0.4, small;
0.5-0.8, moderate; >0.8, large effect).25 Publication bias was assessed visually by looking for
asymmetry in funnel plots and formally with the Egger test. The Egger test is a linear regression test
that examines the association between effect size and SE and is used together with a funnel plot
because visual assessment can be subjective.26 Study heterogeneity was assessed using I2 analysis.
Heterogeneity was considered significant if the I2 value was greater than 50%.27 The quality of the
included articles was assessed using the Newcastle-Ottawa Scale,28 which was originally a 9-point
scale system, but one that we adapted to 7 points. The criteria of demonstration that outcome of
interest was not present at the start of the study and follow-up was long enough for outcomes to
occur were excluded as they were not applicable to the outcome of neurocognitive development. A
score of 5 was the threshold for a study to be considered high quality. Sensitivity analyses using only
high-quality studies were conducted to determine whether the effect size changed.

Additional Analyses
Subgroup analyses based on opioid type, test used, and whether the study controlled for
socioeconomic status were performed to examine whether the status contributed to study
heterogeneity. Details are provided in Table 1 and Table 2.27 Post hoc random-effects
metaregression analysis was performed to identify the association of clinical factors, such as rates of
NAS, sex, and foster care, with differences in effect size. Additional analyses were performed only
on the 6- to 24-month and 3- to 6-year age groups because of the adequate number of studies with
sufficiently large samples (n > 10).

Results
Study Selection
There were 26 studies eligible for inclusion in the meta-analysis. The database search identified 1103
citations. After removal of duplicates, 1095 titles and abstracts were screened. Of these, 189
remained for full-article screening; 52 articles were assessed for eligibility and 26 articles were
excluded. A flow diagram is provided in Figure 1.

Study Characteristics
Details of the cognitive and motor studies have been summarized in eTable 1 and eTable 2 in the
Supplement, respectively. The 26 studies included 1455 children with POE and 2982 controls. There
were 18 unique samples of children because some longitudinal studies reported on the same
cohort.29-54 The studies were all from high-income countries and regions, including the United States
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(n = 11),30,32,34,37-39,41,42,44,46,50 Australia (n = 2),31,33 Europe (n = 4),29,35,40,49 and Israel (n = 1).36
Heroin was used in conjunction with polydrug ingestion in 10 studies,35,36,44,45,49-54 methadone in
conjunction with polydrug ingestion in 13 studies,29-33,37-39,41-43,47,48 and unspecified opioids in
conjunction with polydrug ingestion in 3 studies.34,40,46
Mean (SE) age at cognitive testing was 13 (1.58) months for the toddler group, 4.5 (0.38) years
for the preschool group, and 13 (2.36) years for the school-aged group. Mean (SD) age at motor
testing was 2 (0.45) years. Children were born between 1970 and 2004.
Sixteen30,32,34,36-39,41-44,46,47,50,52,53 studies controlled for socioeconomic status,

Table 1. Cognitive Subgroup Analyses
Ages 6-24 mo
Variable

Subgroup

Overall

NA

No. of
Studies

Ages 3-6 y
P Value for
Heterogeneity

I2, %

SMD (95% CI)

No. of
Studies

P Value for
Heterogeneity

I2, %

SMD (95% CI)

13

−0.52 (−0.74 to −0.31)

71

<.001

13

−0.38 (−0.69 to −0.0.7)

86

<.001

10

−0.61 (−0.88 to −0.33)

72

<.001

7

−0.52 (−0.78 to −0.27)

55

.04

Heroin

1

−0.54 (−0.89 to −0.18)

NA

NA

4

−0.41 (−0.64 to −0.17)

0

.79

Unspecified

2

−0.22 (−0.43 to −0.013)

0

.53

2

0.24 (−0.66 to 1.13)

93

<.001

Controlled for
SES

Yes

8

−0.47 (−0.76 to −0.17)

71

.001

8

−0.20 (−0.59 to 0.19)

88

<.001

No

5

−0.62 (−0.91 to −0.33)

62

.03

5

−0.70 (−0.91 to −0.48)

86

<.001

Test used

BSID

8

−0.40 (−0.60 to −0.20)

35

.15

0

NA

NA

NA

BSID-II

3

−0.57 (−1.00 to −0.14)

83

.003

0

NA

NA

NA

BSID-III

1

−2.25 (−3.06 to −1.44)

NA

NA

0

NA

NA

NA

Griffiths Mental
Development Scales

1

−0.50 (−0.99 to −0.010)

NA

NA

0

NA

NA

NA

Stanford-Binet
Intelligence Scales

0

NA

NA

NA

4

−0.38 (−0.55 to −0.20)

0

.70

MSCA

0

NA

NA

NA

5

−0.43 (−0.77 to −0.08)

60

.04

BSID-II

0

NA

NA

NA

1

0.68 (0.45 to 0.91)

NA

NA

MPMST

0

NA

NA

NA

1

−0.77 (−1.32 to −0.22)

NA

NA

SON

0

NA

NA

NA

1

−0.96 (−1.53 to −0.40)

NA

NA

WPPSI-III

0

NA

NA

NA

1

−0.57 (−1.39 to 0.25)

NA

NA

Main opioid used Methadone

Abbreviations: BSID, Bayley Scales of Infant and Toddler Development; BSID-II, Bayley
Scales of Infant and Toddler Development–Second Edition; BSID-III, Bayley Scales of
Infant and Toddler Development–Third Edition; MPMST, Merill-Palmer Scale of Mental
Tests; MSCA, McCarthy Scales of Children’s Abilities; NA, not applicable; SES,

socioeconomic status; SMD, standardized mean difference; SON, Snijders-Oomen
Nonverbal Intelligence scale; WPPSI-III, Wechsler Preschool and Primary Scale of
Intelligence, third edition.

Table 2. Motor Subgroup Analyses
Ages 6-24 mo
Variable

Subgroup

No. of
Studies

SMD (95% CI)

I2, %

P Value for
Heterogeneity

Overall

NA

14

−0.49 (−0.74 to −0.23)

80

<.001

Main opioid used

Methadone

9

−0.66 (−1.05 to −0.28)

84

<.001

Controlled for SES

Test used

Heroin

3

−0.47 (−0.74 to −0.20)

22

.28

Unspecified

2

−0.03 (−0.26 to 0.19)

57

.30

Yes

8

−0.65 (−1.05 to −0.24)

86

<.001

No

6

−0.35 (−0.68 to −0.01)

73

<.001

BSID

7

−0.33 (−0.54 to −0.12)

37

.14

BSID-II

2

−0.39 (−1.01 to 0.22)

89

.002

MSCA

2

−0.30 (−1.18 to 0.58)

83

.01

BSID-III

1

−3.50 (−4.5 to −2.54)

NA

NA

Griffiths Mental Development Scales

1

−0.67 (−1.16 to −0.17)

NA

NA

Purdue Pegboard Test

1

−0.34 (−0.74 to 0.063)

NA

NA

Abbreviations: BSID, Bayley Scales of Infant and Toddler Development; BSID-II, Bayley
Scales of Infant and Toddler Development–Second Edition; BSID-III, Bayley Scales of
Infant and Toddler Development–Third Edition; MSCA, McCarthy Scales of Children’s

Abilities; NA, not applicable; SES, socioeconomic status; SMD, standardized mean
difference.
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1929,31-33,35-37,39-41,43,45,47-51,53,54 reported rates of NAS, and 2129-31,33,35-38,40,41,43-48,50-54 reported
rates of foster or out-of-home care. The reported rates for NAS ranged from 53% to 93%. The
incidence of NAS was not reported in 1 study, which was attributed to detoxification of the mothers
by the third trimester.49 Rates of out-of-home care ranged from 20% to 72%. In 4 studies,30,38,46,51
all children with POE who were tested were in the care of their mother owing to the differences in
recruitment methods, such as foster care being an exclusion criterion46,51 or having a subsample of
mothers who were functional enough to retain custody of their children.38

Cognitive Tests
For children aged 6 to 24 months, the Bayley Scales of Infant Development (BSID)55 was the most
common cognitive test conducted (n = 8).30-32,36,37,39-41 Other tests included the Bayley Scales of
Infant and Toddler Development–Second Edition (BSID-II)56 (n = 3),33-35 Bayley Scales of Infant and
Toddler Development–Third Edition (BSID-III)57 (n = 1),38 and Griffiths Mental Development Scales58
(n = 1).29 For children 3 to 6 years, the most common test was the McCarthy Scales of Children’s
Abilities59 (MSCA) (n = 5),32,35,43,45,50 followed by the Stanford-Binet Intelligence Scales60 (SB)
(n = 4).31,42,44,46 Other tests included the Weschler Preschool and Primary Scale of Intelligence–III61
(n = 1),49 the Snijders-Oomen Nonverbal Intelligence tests62 (n = 1)48 and the Merrill-Palmer Scale of
Mental Tests63 (n = 1).47 For children 7 to 18 years, the most common test was the Wechsler
Intelligence Scale for Children64 (n = 2)51,52 or the Wechsler Intelligence Scale for Children–Revised65
(n = 1)53 (eTable 1 in the Supplement).

Types of Motor Tests
The most common motor test used was the BSID55 (n = 7),30,31,36,37,39-41 followed by BSID-II56
(n = 2)33,34 and MSCA59 (n = 2).32,54 Other tests used were BSID-III57 (n = 1),38 Griffiths Mental
Development Scales 58 (n = 1),29 and the Purdue Pegboard Test66 (n = 1)44 (eTable 2 in the
Supplement).

Cognitive Scores
For infants aged 0 to 24 months, 13 studies pooling 584 children with POE and 1496 controls
revealed a significant difference in neurocognitive development. Results for children with POE were
lower (d = −0.52; 95% CI, −0.74 to −0.31; P < .001) than those of the controls (Figure 2A).
Heterogeneity was significant at 71%. This incidence was partially accounted for by subgroup analysis
including only studies that tested using the BSID (I2 = 35%) or included exposure to unspecified
drugs (I2 = 0).
For preschool children aged 3 to 6 years, 13 studies pooling 719 children with POE and 1346
controls revealed a significant difference in neurocognitive development. Results for children with
POE were lower (d = −0.38; 95% CI, −0.69 to −0.07; P < .02) than those of controls (Figure 2B).
Heterogeneity was significant at 86%. This incidence was partially accounted for by subgroup
analyses, including only studies that tested using the MSCA (I2 = 60%) and Stanford-Binet
Intelligence Scales (I2 = 0%) or children with exposure to methadone (I2 = 55%) and heroin
(I2 = 0%).
For school-aged children 7 to 18 years, 3 studies pooling 152 children with POE and 140 controls
showed that the difference in neurocognitive development was not significant (d = −0.44; 95% CI,
−1.16 to 0.28; P = .23) (Figure 2C). Heterogeneity was significant at 89%. However, the number of
studies was too small to perform subgroup analysis. All studies were considered high quality.

Motor Outcomes
For all children 6 years or younger, 14 studies pooling 688 children with POE and 1500 controls
revealed a significant difference in motor development. Results for children with POE were lower
(d = −0.49; 95% CI, −0.74 to −0.23; P < .001) than those of the controls (Figure 3). Heterogeneity
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was significant at 80%. This incidence was partially accounted for by subgroup analyses, including
only studies that tested using the BSID (I2 = 37%) or children exposed to heroin (I2 = 22).

Factors Associated With Outcome Differences
Post hoc univariate metaregression analyzing the association between rates of NAS, rates of
nonmaternal or foster care, and SMD between children with POE and controls was performed. No

Figure 2. Cognitive Outcomes Among All Age Groups
A Infants, age 0-24 mo

Control

POE

Favors
Poorer Outcome

Favors
Weight,
Better Outcome %

Mean

SD

10.2

25

114.8

11.3

26

–0.13 (–0.68 to 0.42)

6.6

16.4

64

105.5

15.6

55

–0.45 (–0.81 to –0.08)

8.7

95.0

16.1

41

100.7

20.1

23

–0.32 (–0.83 to 0.19)

7.0

12

102.5

11.4

27

106.5

6.4

17

–0.40 (–1.01 to 0.21)

6.0
7.2

Age, mo

Mean

SD

Strauss et al,39 1976

12

113.4

Wilson et al,41 1981

9

98.3

Rosen and Johnson,37 1982

6

Kaltenbach and Finnegan,32 1989

SMD IV, Random,
95% CI

Total

Source

Van Baar et al,40 1990

Total

6

106.0

13.0

27

107.0

13.0

37

–0.08 (–0.57 to 0.42)

Ornoy et al,36 1996

24

104.0

15.8

37

112.0

14.9

47

–0.52 (–0.96 to –0.08)

7.9

Bunikowski et al,29 1998

12

100.5

9.3

27

107.9

17.2

42

–0.50 (–0.99 to –0.01)

7.3

Hans and Jeremy,30 2001

12

Messinger et al,34 2004

12

107.0
88.5

14.3
10.7

33
79

109.0
91.6

13.7
12.4

45
960

–0.14 (–0.59 to 0.31)
–0.25 (–0.48 to –0.02)

7.7
10.3

Hunt et al,31 2008

18

88.2

16.4

79

105.0

23.0

61

–0.85 (–1.20 to –0.51)

8.9

Nygaard et al,35 2015

12

92.2

14.3

66

98.7

8.9

58

–0.53 (–0.89 to –0.18)

8.8

Levine and Woodward et al,33 2018

24

76.1

17.6

68

92.4

16.4

88

–0.96 (–1.29 to –0.62)

9.1

Serino et al,38 2018

12

95.4

3.9

11

102.6

2.9

37

–2.25 (–3.07 to –1.43)

4.3

1496

–0.52 (–0.74 to –0.31)

100.0

584

Total (95% CI)
Heterogeneity: τ2 = 0.10; χ2 = 40.8112; P < .001; I 2 = 71%,

–4

Test for overall effect: z = 4.73, P < .001
B

–2

0

2

4

SMD IV, Random, 95% CI

Preschool children, age 3-6 y
Control

POE
Mean

Total

SD

Mean

SD

Total

SMD IV, Random,
95% CI

Favors
Poorer Outcome

Favors
Weight,
Better Outcome %

Source

Age, y

Wilson et al,50 1979

3.0

88.7

14.6

22

97.4

14.6

20

–0.58 (–1.20 to 0.03)

Lifschitz et al,43 1985

3.0

87.9

14.5

51

89.4

10.8

41

–0.11 (–0.53 to –0.30)

8.1

Rosen and Johnson,47 1985

3.0

44.6

2.1

39

46.3

2.3

21

–0.77 (–1.32 to –0.22)

7.3
8.5

6.9

Bauman and Levine,42 1986

3.0

92.7

15.4

70

100.4

18.4

70

–0.45 (–0.79 to –0.12)

Kaltenbach and Finnegan,32 1989

3.5

106.5

13.0

27

106.1

13.1

17

0.03 (–0.58 to 0.64)

6.9

Van Baar and de Graaff,48 1994

3.5

99.0

9.0

23

109.0

11.0

32

–0.96 (–1.53 to –0.40)

7.2

Ornoy et al,45 2003

3.0

101.7

13.6

35

108.4

12.2

24

–0.51 (–1.03 to 0.02)

7.4

Messinger et al,34 2004
Hunt et al,31 2008

3.0
6.0

83.0
99.9

1.6
15.1

78
67

82.6
107.5

0.4
13.4

918
44

0.68 (0.45 to 0.91)
–0.52 (–0.91 to –0.14)

8.9
8.2

Nair et al,44 2008

6.0

80.1

10.1

111

83.3

11.2

62

–0.30 (–0.62 to 0.01)

8.6

Pulsifer et al,46 2008

5.0

86.7

11.3

113

89.5

13.0

31

–0.24 (–0.64 to 0.16)

8.1

Nygaard et al,35 2015

4.5

102.3

15.1

71

114.3

12.1

54

–0.86 (–1.23 to –0.49)

8.3

Walhovd et al,49 2015

4.5

94.9

7.2

12

99.4

8.0

12

–0.57 (–1.39 to 0.25)

719

Total (95% CI)

1346

Heterogeneity: τ2 = 0.28; χ2 = 87.5912; P < .001; I 2 = 86%,

100.0
–2

Test for overall effect: z = 2.37, P < .02
C

5.7

–0.38 (–0.69 to –0.07)
–1

0

1

2

SMD IV, Random, 95% CI

School-aged children, age 7-18 y
POE

Control

Source

Age, y

Mean

SD

Total

Robey et al,52 2014

Mean

SD

Total

SMD IV, Random,
95% CI

Favors
Poorer Outcome

Favors
Weight,
Better Outcome %

14.0

90.47

33.3

59

94.8

34.3

46

–0.13 (–0.51 to 0.26)

Nygaard et al,53 2016

8.5

97.90

16.0

55

116.1

14.2

48

–1.19 (–1.61 to –0.77)

33.2

Ornoy et al,51 2016

9.0

88.80

11.4

38
152

88.9

13.3

46
140

–0.01 (–0.44 to 0.42)
–0.44 (–1.16 to 0.28)

33.0

Total (95% CI)

33.8

100.0

Heterogeneity: τ2 = 0.37; χ2 = 18.562; P < .001; I 2 = 89%,
Test for overall effect: z = 1.19, P < .23

–2

–1

0

1

2

SMD IV, Random, 95% CI

IV indicates inverse variance method; POE, prenatal opioid exposure; and SMD, standardized mean difference.
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significant associations between rates of NAS and SMD were found for the age groups 6 to 24
months (B = 0.002; 95% CI, −0.013 to 0.016; P = .79) and 3 to 6 years (B = −0.00; 95% CI, −0.008
to 0.007; P = .96). Similarly, no significant associations between rates of nonmaternal care and SMD
were found for the age groups 6 to 24 months (B = −0.001; 95% CI, −0.008 to 0.007; P = .82) and
3 to 6 years (B = −0.003; 95% CI, −0.014 to 0.008; P = .57).

Evaluation of Bias
There was no evidence of publication bias in studies comparing cognitive scores of infants (SE, 1.05;
95% CI, −1.11 to 3.46; P = .13) and preschool children (SE, 2.15; 95% CI, −2.07 to 7.29; P = .19) using
funnel plot inspection and the Egger test. Publication bias for adolescents was not assessed because
there were inadequate numbers (n = 3) of included studies. There was evidence of publication bias
in studies comparing motor scores of all children (SE, 1.71; 95% CI, 1.81-9.19; P = .004).

Discussion
This systematic review and meta-analysis suggests that differences in neurocognitive testing
associated with POE occur across a wide age range. The results agree with our hypothesis that POE
has a negative association with cognitive and motor outcomes, these issues are apparent from as
early as 6 months, and they persist during school age. To put this finding in perspective, an SMD of
0.38 to 0.52 corresponds to a moderate effect size,25 equivalent to 5.7 to 7.8 IQ points on a
population level.67,68 Therefore, we expect that up to 6.3% of children with POE will have an IQ score
2 SDs below normal compared with 2.3% of children in a normally distributed population, suggesting
that children with POE are 3 times more likely to have severe intellectual disability according to the
Diagnostic and Statistical Manual of Mental Disorders, 5th edition69 criteria. This difference is
significant for children with POE as they are already vulnerable given their tenuous living
circumstances and increased risk of neglect and abuse,11 as well as their propensity to have
behavioral and attention deficits,70 all of which contribute to poorer academic, social, and lifestyle
outcomes.30,34
The results of our analysis of motor outcomes are similar to those of cognitive outcomes.
Children with POE have poorer motor development compared with healthy controls. We found a
difference of 0.49—a small to moderate effect size. Deficits in gross motor and fine motor function

Figure 3. Motor Results in Children Aged 0 to 6 Years
POE

Control

Source

Age

Mean

SD

Strauss et al,39 1976

12.0 mo

102.80

Wilson et al,41 1981

9.0 mo

90.40

Rosen and Johnson,37 1982

6.0 mo

Kaltenbach and Finnegan,32 1989

3.5 y

van Baar,40 1990

6.0 mo

SMD IV, Random,
95% CI

Favors
Poorer Outcome

Favors
Weight,
Better Outcome %

Total

Mean

11.00

25

110.40

9.80

26

–0.72 (–1.29 to –0.15)

6.4

15.90

64

99.00

14.50

55

–0.56 (–0.93 to –0.19)

7.9

101.03

18.20

41

105.13

14.20

23

–0.24 (–0.75 to 0.27)

6.8

52.29

8.10

27

50.44

12.00

17

0.19 (–0.42 to 0.79)

6.1

118.00

18.00

27

114.00

21.00

37

0.20 (–0.30 to 0.70)

6.9

SD

Total

Ornoy et al,36 1996

24.0 mo

96.60

13.30

30

100.90

14.50

47

–0.30 (–0.76 to 0.16)

7.2

Bunikowski et al,29 1998

12.0 mo

100.80

13.60

27

111.40

16.90

42

–0.67 (–1.16 to –0.17)

6.9

Hans and Jeremy,30 2001

24.0 mo

100.00
48.90

14.20
9.00

33
64

108.00
55.80

14.90
10.20

45
52

–0.54 (–1.00 to –0.08)
–0.72 (–1.10 to –0.34)

7.2
7.8

Moe,54 2002

4.5 y

Messinger et al,34 2004

12.0 mo

88.90

14.20

79

90.00

12.30

939

–0.09 (–0.32 to 0.14)

8.8

Hunt et al,31 2008

18.0 mo

107.50

16.80

79

110.13

14.70

61

–0.16 (–0.50 to 0.17)

8.1

Nair et al,44 2008

6.0 y

3.80

1.90

113

4.50

2.60

31

–0.34 (–0.74 to 0.06)

7.7

Levine and Woodward,33 2018

24.0 mo

82.94

20.54

68

96.10

16.38

88

–0.72 (–1.04 to –0.39)

8.2

Serino et al,38 2008

12.0 mo

95.00

2.10

11

101.40

1.70

37

–3.51 (–4.50 to –2.51)

3.9

1500

–0.49 (–0.74 to –0.23)

100.0

Total (95% CI)

688

Heterogeneity: τ2 = 0.18; χ2 = 65.9213; P < .001; I 2 = 80%,
Test for overall effect: z = 3.74, P < .001

–4

–2

0

2

4

SMD IV, Random, 95% CI

IV indicates inverse variance method; POE, prenatal opioid exposure; and SMD, standardized mean difference.
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are associated with poorer executive function.71 Thus, our findings point to opioids being associated
with overall neurodevelopment in infants and preschool children both directly and indirectly, as a
child’s developmental trajectory is also influenced by his or her physical ability to experience and
interact with the world.72
Poor neurodevelopmental outcomes in children with POE, even from an early age, is not novel
information.31,73 However, our data appear to indicate that neurodevelopment did not improve after
preschool and worsened by school age. The cause of this outcome is unclear. During preschool,
children may receive considerably more individual attention than at a later time in education, with
the reduced intervention possibly leading to worsening cognitive abilities. Regardless of the cause,
this hampered neurodevelopment has serious implications. For example, a data linkage study by Oei
et al74 demonstrated that performance on curriculum-based tests of Australian children with a
history of NAS declined as the children aged and that, by high school, the results of the children with
NAS were worse than those of children 2 years younger without NAS. However, there were a limited
number of studies assessing children after school entry in the present meta-analysis, and this
knowledge gap should be addressed in future studies.
There are considerable individual and societal consequences of poor neurocognitive
performance. Neurocognitive performance is strongly correlated with future academic
achievement.75 School underachievement is reported to lead to students dropping out after failing
to meet examination requirements or finishing school with poorer qualifications.76 Such individuals
receive lower wages and are more likely to be unemployed.77 Academic failure is also associated with
youth delinquency78 as well as early initiation of alcohol and illicit substance use.79 High criminal
rates and substance use further affect the country through the justice system and police
expenditures, as well as public health care expenditures.76 Therefore, poor neurocognitive
performance in childhood and adolescence may lead to financial problems for the individual owing
to difficulties with employment and incur societal costs associated with youth delinquency and
substance use. The consequences are likely to be passed on intergenerationally as the deficits
associated with NAS are likely to influence parenting by NAS-affected adults.
Opioid substitution therapies limit fetal exposure to the lability of short-acting opioids, such as
heroin, and stabilize the intrauterine environment.80 Opioid-dependent women who receive
substitution therapy during their pregnancy are more stable psychologically and physically, receive
more comprehensive antenatal care, and have better neonatal outcomes than women who are not
receiving opioid substitution therapies.81 Our study is retrospective and observational; more studies
need to be conducted before the current standard of care is changed.
In addition, the cause of these poor outcomes cannot be absolutely determined from the
studies reviewed herein owing to the combination of inherited epigenetic changes,70 poor parental
education, direct effect of opioids on brain volume,17 or the child’s home environment.44 Overall,
there is substantial variability within each subgroup for neurocognitive outcomes as the children age,
as evidenced by the widening 95% CIs, suggesting that children have the potential to overcome early
discrepancies and environmental and other factors might possibly improve future outcomes. A
meta-analysis examining the use of cognitive interventions for children with neurodevelopmental
disorders82 has shown that improvement in neurocognitive functioning across all domains is
possible, albeit to different degrees.

Future Research
Our results suggest that conducting high-quality longitudinal cohort studies may be warranted to
investigate the neurocognitive outcomes of children with POE until adolescence. In addition, studies
using cohort and randomized trial designs should assess whether other factors (eg, foster care and
parenting) contribute to the outcomes of children with POE. While we acknowledge that such
studies will require substantial funding, personnel, and time, it is worthwhile since our results suggest
that children with POE never reach the neurocognitive level of their peers, which increases their risk
of poor school performance, unemployment,76 and even criminal activity.78 This outcome raises
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concern not only for the individual, but for his or her family, community, and society, considering the
rapid rise of prescription opioid use and abuse around the world.

Limitations
This meta-analysis has limitations. To include all available studies, we used hand-searching, which
may have introduced citation bias. However, publication bias was not detected for cognitive
outcomes. Although there was publication bias for motor outcomes, the trim-and-fill method, which
is commonly used to correct for funnel plot asymmetry, is not recommended in this case owing to
the high level of heterogeneity.22
Heterogeneity was significant for all analyses, although it was expected owing to the inclusion
of multiple opioid types, various neurodevelopmental tests used, and clinical factors.22 Nevertheless,
we attempted to explain the heterogeneity via subgroup analysis. Although heterogeneity was not
completely accounted for, our results are based on a random-effects model, taking heterogeneity
into consideration.
A key limitation is that we were unable to contact some authors for missing data, resulting in the
exclusion of studies without means and SDs. We also had incomplete information on rates of NAS,
rates of foster care, sex, parental educational levels, and substances used in pregnancy. In addition,
the articles were limited to those published in English.
We performed post hoc metaregression on the association between rates of foster care, rates
of NAS, and cognitive differences (SMD), but we did not find a significant association. One caveat is
that post hoc analyses are not recommended because findings are not robust and are prone to
inaccurate conclusions derived from observational patterns.83 Our intention was to generate
hypotheses that could potentially explain our results and inform future studies.

Conclusions
This systematic review and meta-analysis suggests that POE is negatively associated with
neurocognitive and motor development. These differences begin from age 6 months and persist in
adolescence. The exact cause and the association of these findings with clinical factors and
environmental adversities are unclear but suggest that children with POE should be provided longterm support and intervention beyond infancy.
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